InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,716.80
(
0.19%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.25
(
0.04%
)
Bitcoin
62,978.06
(
0.12%
)
Post# of 193
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

TheFinalCD

Send PM Follow Ignore
Followers 4053
Posts 151321
Boards Moderated 4
Alias Born 08/05/2009

TheFinalCD

Member Level

Re: Pineapple1 post# 21

Wednesday, 06/13/2018 7:53:37 AM

Wednesday, June 13, 2018 7:53:37 AM

Post# of 193
Flex Pharma, Inc. (FLKS), a clinical-stage biotechnology company, today announced that the Company is ending its ongoing Phase 2 clinical trial investigations of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT) due to oral tolerability concerns observed in both studies, in a subset of patients being treated, with the oral disintegrating tablet formulation at 30 mg, taken three times a day.

Always consult an Investment Professional, my posts are my own
opinions, and not for investing decisions!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up